Upon oral ingestion, BPC-157 directly contacts the gastric and intestinal lining, promoting mucosal integrity, accelerating ulcer healing, and protecting against various digestive insults including NSAIDs and stress
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
BPC-157 may be particularly beneficial for: Athletes recovering from injuries or seeking faster recovery between training sessions Individuals with chronic tendon or joint issues People suffering from digestive disorders like IBS, Crohns, or ulcerative colitis Those recovering from surgery, especially orthopedic procedures Individuals with nerve injuries or neuropathic pain Men seeking performance optimisation and injury prevention Women dealing with gut health issues or hormone-related joint concerns Are There Side Effects
Yes, and many clinicians intentionally prescribe both peptides concurrently for patients with combined goals
Semaglutide : Well-characterized GI side effect profile over 7+ years
